Extending time to disease progression or survival in cancer patients
AssigneeGenentech, Inc.
InventorsMika K. Derynck, Stephen M. Kelsey
Life of this patent
Estimating the term…
Abstract
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
Claims37
A method for extending time to disease progression (TTP) or survival in a cancer patient comprising administering a HER dimerization inhibitor to the patient in an amount which extends TTP or survival in the patent, wherein the patient's cancer displays HER activation.
A method for extending time to disease progression (TTP) or survival in a patient with ovarian, peritoneal, or fallopian tube cancer comprising administering pertuzumab to the patient in an amount which extends TTP or survival in the patent, wherein the patient's cancer displays HER2 activation.
Dependencies are inferred from the claim text.